Cystic Fibrosis — Initial data
in 2026
Prime Medicine is also progressing an in vivo Cystic Fibrosis (CF) program with support from the Cystic Fibrosis Foundation, and anticipates generating preclinical proof of concept data in 2026.Source filing
PRME biotech catalysts & pipeline
PRIME MEDICINE INC · Data as of 2026-09-08
Upcoming catalysts
PM647 — IND submission
Q3 2026
Prime Medicine expects to submit an IND and/or CTA for PM647 in the third quarter of 2026, with initial clinical data expected in 2027.Source filing
AATD program — Initial data
in 2027
including the timing of the filing of IND and/or CTA applications in mid-2026 and 1H 2026, respectively, and the timing of initial data for both programs in 2027;Source filing
Alpha-1 Antitrypsin Deficiency (AATD) — Initial data
in 2027
Prime Medicine expects to file an IND and/or CTA for its AATD program in mid-2026, and to report initial clinical data from both WD and AATD programs in 2027.Source filing
PM359 — NDA/BLA submission
1H 2027
FDA grants Regenerative Medicine Advanced Therapy designation to PM359; continued regulatory engagement with the FDA toward a BLA submission for PM359 in 1H 2027 --Source filing
PM577 — Initial data
2027
• Continue study startup activities for the global Phase 1/2 clinical trial of PM577a in WD, initial clinical data in 2027.Source filing
PM577 — IND submission
H1 2027
Prime Medicine expects to file an investigational new drug application (IND) and/or clinical trial application (CTA) for its WD program in the first half of 2027 and for its AATD program in mid-2026; initial clinical data from both studies are expected in 2027.Source filing
PM647 — Initial data
2027
Prime Medicine expects to submit an IND and/or CTA for PM647 in the third quarter of 2026, with initial clinical data expected in 2027.Source filing
Wilson Disease — Initial data
in 2027
Prime Medicine expects to file an IND and/or CTA for its AATD program in mid-2026, and to report initial clinical data from both WD and AATD programs in 2027.Source filing
Wilson's Disease — Initial data
2027
Prime Medicine is currently advancing in vivo programs to cure two of the largest genetic liver diseases, Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD), with initial clinical data from both programs expected in 2027.Source filing
Wilson's Disease program — Initial data
in 2027
including the timing of the filing of IND and/or CTA applications in mid-2026 and 1H 2026, respectively, and the timing of initial data for both programs in 2027;Source filing